Sabatolimab safety tracked in extended cancer study
NCT ID NCT05201066
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 30 times
Summary
This study looks at the long-term safety of the drug sabatolimab in people with myelodysplastic syndromes or chronic myelomonocytic leukemia who already benefited from it in a previous trial. About 33 participants will continue treatment and be monitored for side effects. The goal is to gather more safety information, not to test if the drug works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Huntsman Cancer Institute Univ of Utah
Salt Lake City, Utah, 84112 0550, United States
-
Novartis Investigative Site
Clayton, Victoria, 3168, Australia
-
Novartis Investigative Site
Florianópolis, Santa Catarina, 88020-210, Brazil
-
Novartis Investigative Site
Vancouver, British Columbia, V5Z 1M9, Canada
-
Novartis Investigative Site
Changchun, Jilin, 130021, China
-
Novartis Investigative Site
Tianjin, 300020, China
-
Novartis Investigative Site
Prague, 128 08, Czechia
-
Novartis Investigative Site
Toulouse, 31059, France
-
Novartis Investigative Site
Freiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
Alexandroupoli, 681 00, Greece
-
Novartis Investigative Site
Pátrai, 265 04, Greece
-
Novartis Investigative Site
Brescia, BS, 25123, Italy
-
Novartis Investigative Site
Florence, FI, 50134, Italy
-
Novartis Investigative Site
Genova, GE, 16132, Italy
-
Novartis Investigative Site
Milan, MI, 20162, Italy
-
Novartis Investigative Site
Roma, RM, 00133, Italy
-
Novartis Investigative Site
Fukushima, 960 1295, Japan
-
Novartis Investigative Site
Kuala Lumpur, 59100, Malaysia
-
Novartis Investigative Site
Badalona, Barcelona, 08916, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Zurich, 8091, Switzerland
-
Novartis Investigative Site
Izmir, 35100, Turkey (Türkiye)
-
Oregon Health Sciences University
Portland, Oregon, 97239, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sabatolimab (a cancer immunotherapy drug, given as an infusion)
What this could lead to
If successful, this study could show that long-term sabatolimab is safe for people with certain blood cancers, supporting its continued use.
What could go wrong
This is a small, early-phase safety study with only 33 participants, so results may not apply to everyone. It does not test whether the drug works better than other options.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.